DreaMed
DreaMed is a healthcare technology company focused on AI-driven solutions for diabetes management. Founded in 2014 and based in Israel, DreaMed initially developed artificial pancreas technology and has since expanded to include AI-based clinical decision support systems. The company aims to improve diabetes treatment accessibility worldwide by offering expert-level care recommendations through its proprietary algorithms. DreaMed's core products include Advisor Pro, an FDA-cleared AI platform that provides personalized insulin therapy recommendations for type 1 diabetes patients, and endo.digital, which optimizes insulin treatment plans for both type 1 and type 2 diabetes patients. The company also developed an artificial pancreas algorithm that has been integrated into Medtronic's Minimed 780G insulin pump system. DreaMed's solutions are clinically validated and utilized in leading healthcare institutions, addressing the global shortage of endocrinologists and enhancing diabetes care for patients.
Work at DreaMed in HR or recruiting? Claim this page
Headcount trend
DreaMed went from 29 employees in May 2023 to 39 in Apr 2025. Nov 2024 to Apr 2025: 3 people joined, 0 left.
Headcount data through Apr 2025
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Sep 2020 | Funding | $5M | 1 | |
| Jul 2016 | Venture | $3.3M | – | – |
| Apr 2015 | Seed | $2M | 1 |
Org structure
Headcount by department
Peer reviews
Worked with someone at DreaMed?
Anonymous peer reviews on OffTheRecord
Similar companies
DreaMed FAQ
How many employees does DreaMed have?
DreaMed has about 39 employees, up 5.4% over the 3 months to Apr 2025.
How much funding has DreaMed raised?
DreaMed has raised $10.3M in total funding.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.